{"pageContent": "Purpose of review: Androgen deprivation therapy is the cornerstone treatment for men with de novo or recurrent metastatic prostate cancer. Unfortunately, androgen deprivation therapy is primarily palliative, with nearly all men progressing to an androgen-independent state. Hormone-refractory prostate cancer presents significant management challenges and is the focus of this review.", "metaData": {"source": "Prostate Cancer: Community Education and Disparities in Diagnosis and Treatment\nhttps://pubmed.ncbi.nlm.nih.gov/33683758/"}}